Literature DB >> 2255221

Fatal hypernatremia from exogenous salt intake: report of a case and review of the literature.

K G Moder1, D L Hurley.   

Abstract

Hypernatremia is a common electrolyte disturbance, most often caused by volume depletion. Hypernatremia due to sodium excess occurs less frequently, and fatal hypernatremia solely from ingestion of table salt is rare. We describe a 41-year-old man who had seizures and hypernatremia after ingestion of a supersaturated salt water solution intended for gargling. He had consumed approximately a third cup of table salt (approximately 70 to 90 g of salt or 1,200 to 1,500 meq of sodium). His initial serum sodium concentration was 209 meq/liter. Hypotonic fluid therapy was given to provide free water and to correct the hypernatremia gradually. Our patient, however, failed to recover from the initial insult and died 3 days later. Review of the literature revealed 10 adult and 20 pediatric cases of hypernatremia attributable to exogenous intake of salt. The type of therapy (fluid or peritoneal dialysis), the type of fluid used, and the rate of correction of hypernatremia did not influence survival. The age of the patient and the initial serum sodium concentration were the most important prognostic indicators. Both very young patients and those with lesser degrees of hypernatremia had a better rate of survival than did other patients. In addition, our review illustrates the surprisingly small amount of salt that can cause severe hypernatremia and the danger of using salt or saline as an emetic.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2255221     DOI: 10.1016/s0025-6196(12)62194-6

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  15 in total

1.  Extreme Neonatal Hypernatremia and Acute Kidney Injury Associated with Failure of Lactation.

Authors:  Gianfranco Tomarelli; Daniela Arriagada; Alejandro Donoso; Franco Diaz
Journal:  J Pediatr Intensive Care       Date:  2019-11-26

2.  Survival with extreme hypernatremia at 209 mmol/l.

Authors:  L Portel; G Hilbert; D Gruson; G Gbikpi-Benissan; J P Cardinaud
Journal:  Intensive Care Med       Date:  1998-02       Impact factor: 17.440

3.  Sodium thiosulfate during cisplatin-based hyperthermic intraperitoneal chemotherapy is associated with transient hypernatraemia without clinical sequelae.

Authors:  Anais Alonso; Winston Liauw; Helen Kennedy; Nayef A Alzahrani; David L Morris
Journal:  Pleura Peritoneum       Date:  2022-05-02

4.  Intracranial Hemorrhage Caused by Acute-Onset Severe Hypernatremia.

Authors:  Takahiro Goshima; Teruhiko Terasawa; Mitsunaga Iwata; Asako Matsushima; Tomonori Hattori; Hiroshi Sasano
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-09-09

Review 5.  Cell volume regulation: a review of cerebral adaptive mechanisms and implications for clinical treatment of osmolal disturbances: II.

Authors:  H Trachtman
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

6.  Management of salt poisoning in an extremely low birth weight infant.

Authors:  J D Roscelli; C E Yu; W M Southgate
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

Review 7.  Disturbances of sodium in critically ill adult neurologic patients: a clinical review.

Authors:  Martin Tisdall; Matthew Crocker; Jonathan Watkiss; Martin Smith
Journal:  J Neurosurg Anesthesiol       Date:  2006-01       Impact factor: 3.956

8.  A review of drug-induced hypernatraemia.

Authors:  George Liamis; Haralampos J Milionis; Moses Elisaf
Journal:  NDT Plus       Date:  2009-07-16

9.  Mechanisms for the Sour Taste.

Authors:  Jin Zhang; Hojoon Lee; Lindsey J Macpherson
Journal:  Handb Exp Pharmacol       Date:  2022

10.  Plasma exchange successfully treats central pontine myelinolysis after acute hypernatremia from intravenous sodium bicarbonate therapy.

Authors:  Kyung Yoon Chang; In-Hee Lee; Gi Jun Kim; Kangwon Cho; Hoon Suk Park; Hyung Wook Kim
Journal:  BMC Nephrol       Date:  2014-04-04       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.